The agreement aims to support the development of an innovative and sustainable pharmaceutical ecosystem, enhance local manufacturing capabilities, and expand the use of advanced technologies across the sector.

It also aims to strengthen supply chain security by increasing in-country value and promoting partnerships that support the continuity and availability of pharmaceutical products.

Supporting healthcare resilience

The MoU is expected to strengthen the resilience of the UAE healthcare sector and support the sustainable availability of medicines nationwide.

Both parties will support initiatives to enhance the readiness and long-term sustainability of the country's pharmaceutical ecosystem.

Developing national talent

The agreement includes talent development and capacity-building programmes designed to strengthen national competencies through training, knowledge exchange and professional development opportunities.

It will also provide Emirati talent and students with access to academic, internship and practical training programmes in the pharmaceutical industry.

Driving innovation and research

In the fields of innovation, research and development, the memorandum aims to support a regulatory environment that accelerates the introduction of innovative therapies and expands access to advanced treatments.

The partnership will also encourage greater participation by UAE-based institutions and stakeholders in research and product development projects related to the company's activities.

Enhancing global competitiveness

The collaboration is expected to strengthen the UAE's pharmaceutical sector, expand opportunities for innovation and industry growth, and reinforce the country's standing as a leading regional and global hub for advanced pharmaceutical manufacturing.